Postponement of AB Science Annual General Shareholders’ meeting
22/05/2020 – AB Science announces the postponement of its annual general shareholders’ meeting
22/05/2020 – AB Science announces the postponement of its annual general shareholders’ meeting
07/05/2020 – AB Science will host a live webcast on masitinib in combination with isoquercetin for the treatment of COVID-19 on Monday May 11, 2020
07/05/2020 – AB Science will present results from its Phase 3 study in severe asthma at the EEACI 2020 Annual Congress
06/05/2020 – AB Science granted authorization by ANSM to initiate Phase 2 study evaluating masitinib in combination with isoquercetin for the treatment of COVID-19
30/04/2020 – AB Science reports its annual financial results as of 31 December, 2019
03/04/2020 – A letter to our stakeholders on COVID-19 pandemic impact on AB Science clinical studies
31/03/2020 – AB Science today announces that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application, allowing the Company to initiate its masitinib Phase 3 study (AB19001) in amyotrophic lateral sclerosis
09/03/2020 – AB Science provides a summary of the live webcast held on March 6 2020 with key opinion leaders on progressive froms of multiple sclerosis
02/03/2020 – AB Science announces a new fundraising of EUR 12.3 million
20/02/2020 – AB Science announces positive top-line Phase 2B/3 results for oral masitinib in progressive forms of multiple sclerosis